Treatment Type Segment Analysis: Anti-allergy Drugs (Largest Segment) vs Immunotherapy (Fastest-Growing Segment)

The anti-allergy drugs segment dominated the allergy therapeutics market, accounting for 82.32% of the market share in 2026. Its leadership is supported by the broad use of antihistamines, corticosteroids, decongestants, and other medications that provide rapid symptom relief for a wide range of allergic conditions. Their widespread availability, established clinical use, and ability to effectively manage seasonal and chronic allergies continue to sustain strong demand across healthcare settings.

Immunotherapy is expected to experience the fastest growth over the forecast period as treatment strategies increasingly focus on addressing the underlying immune response rather than providing temporary symptom control. Advances in allergen-specific therapies, improved treatment protocols, and growing awareness of long-term disease management are encouraging greater adoption of immunotherapy for patients with persistent allergic disorders.

Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Retail Pharmacies (Fastest-Growing Segment)

Hospital pharmacies held 57.88% of the market share in 2026, supported by their central role in dispensing prescription allergy medications and specialized therapies for patients requiring physician supervision. Their close integration with hospitals and specialty clinics ensures timely access to advanced treatments, supports medication management, and enhances continuity of patient care for moderate to severe allergic conditions.

In the allergy therapeutics market, retail pharmacies are projected to be the fastest-growing distribution channel due to increasing accessibility of allergy medications, expanding pharmacy networks, and rising consumer preference for convenient healthcare services. Improved availability of prescription refills, pharmacist-led guidance, and growing demand for community-based healthcare solutions are contributing to the rapid expansion of this segment.

Route of Administration Segment Analysis: Oral (Largest Segment) vs Inhalers (Fastest-Growing Segment)

The oral route of administration captured 54.7% of the market share in 2026, driven by its convenience, ease of use, and strong patient acceptance. Oral tablets and capsules are widely prescribed for managing common allergic conditions because they support straightforward dosing, encourage treatment adherence, and are suitable for long-term symptom management across diverse patient groups.

The inhalers segment is anticipated to record the fastest growth as respiratory allergies and allergy-related airway conditions receive increasing clinical attention. Growing demand for targeted drug delivery, rapid symptom relief, and improved pulmonary treatment effectiveness is supporting wider adoption of inhaler-based therapies, while ongoing advancements in inhalation device technology continue to enhance treatment outcomes.